GPX4 and metabolic dysfunction-associated steatohepatitis: Studies have demonstrated that treatment with the ferroptosis inducer RSL-3 can decrease hepatic expression of GPX4, leading to more severe symptoms in an MCD-induced NASH mice model (66).